Management of Gout in Patients With Solid Organ Transplants
Hyperuricaemia is known to occur in up to 80% of transplant recipients receiving ciclosporin. Gout is less common, occurring in up to 28%. Although the same therapies are used for the management of gout as in the general population, careful consideration must be given to adverse effects and drug interactions with immunosuppressive therapies in transplant recipients. There is a significant interaction between XO inhibitors and AZA, which results in myelosuppression. Further discussion is beyond the scope of this review, but the literature has been reviewed recently.
Rheumatology. 2013;52(1):34-44. © 2013 Oxford University Press